[{"from": "human", "value": "Could you give me a brief overview of this molecule? [H+1].[H+1].[H+1].[C][C][=N][C][=C][Branch2][Branch1][=Branch2][C][=Branch1][Branch1][=C][Ring1][=Branch1][O-1][C][N][Branch2][Ring2][#Branch1][C][C][N][Branch2][Ring1][O][C][C][=C][Branch2][Ring1][Ring2][C][=Branch1][S][=N][C][=C][Ring1][=Branch1][C][O][P][=Branch1][C][=O][Branch1][C][O-1][O-1][C][O-1][C][C][=Branch1][C][=O][O-1][C][C][=Branch1][C][=O][O-1][C][O][P][=Branch1][C][=O][Branch1][C][O-1][O-1].[Na+1].[Na+1].[Na+1].[Mn+2]"}, {"from": "gpt", "value": "The molecule is a contrast agent delivered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver. It has two parts, paramagnetic manganese (II) ions and the chelating agent fodipir (dipyridoxyl diphosphate, DPDP). Normal liver tissue absorbs the manganese more than abnormal or cancerous tissue. The manganese shortens the longitudinal relaxation time (called T1), making the normal tissue appear brighter in MRIs. This enhanced contrast allows lesions to be more easily identified. Acute toxicity studies in mice, rats and dogs using IV administration showed mangafodipir to have low to moderate toxicity. Repeat dose toxicity studies were conducted in rats, cynomologous monkeys and dogs. The liver and to a lesser extent the kidney were target organs of toxicity."}]